C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD

Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in Patients With COPD: Results From Replicate Phase 3 Trials

Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5005 F. Sciurba, A. Anzueto, T. Rheault, T. Bengtsson, K. Rickard

Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in the Enhance-1 Phase 3 Trial of Ensifentrine in COPD

Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5006 F. Sciurba, R. Wise, T. Rheault, T. Bengtsson, K. Rickard

Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Improves COPD Symptoms and Quality of Life in the Phase 3 Enhance-1 Trial

Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5007 F. Sciurba, T. Rheault, T. Bengtsson, K. Rickard